secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001628280-26-013552
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion to acquire Corstasis for $75M upfront; adds Enbumyst nasal spray for heart failure edema
--------------------------------------------------------------------------------

- Esperion acquires Corstasis for $75M cash upfront; up to $180M in milestones plus low double-digit royalties on Enbumyst sales.
- Enbumyst (bumetanide nasal spray) is first FDA-approved nasal spray diuretic for edema in CHF, hepatic, renal disease (approved Sep 2025).
- Esperion expects to leverage its cardiovascular commercial infrastructure to drive double-digit revenue growth; addresses $4B+ U.S. market.
- Transaction financed via existing credit facilities and royalty monetization; expected close Q2 2026.
- Corstasis also developing subcutaneous multidose pen injector; complements Esperion's pipeline in metabolic, hepatic, renal disease.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828026013552/0001628280-26-013552-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828026013552/espr-20260302.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-013552

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer